Peptide firm Diatide to go public

Peptide imaging agent developer Diatide of Londonderry, NH, plans

on issuing an initial public offering in the next several weeks

that will raise $25 million to fund ongoing product development.

The firm will price its stock at $10 to $12 a share, according

to president Richard Dean. Diatide's lead product is a technetium-99m-labeled

agent for detection of deep vein thrombosis.